CICL-207
DC67515
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | E20 |
| Synonyms | S-lipid E20, Lipid E20, E20 S-lipid |
| SMILES | CCCCCCCCC(CCCCCC)OC(=O)CCCCCCC(O)CN(CCCCCCC(=O)O)CC(O)CCCCCCC(=O)OC(CCCCCC)CCCCCCCC |
| Formula | C55H107NO8 |
| M.Wt | 910.46 |
| Purity | Not available |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Liang D, Qi Y, Han H, et al. Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. Published online September 8, 2026. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| E20 | 35.9 | Ionizable lipid |
| DOPE | 24.2 | Helper phospholipid |
| Cholesterol | 38.7 | Sterol |
| DMG-PEG2000 | 1.2 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation weight calculator
The cited formulation and available component molecular weights are pre-filled. Enter the exact molecular weight for any substituted material before calculating.
The 4 reported lipid components total 100 mol%.
| Component | Molecular weight (g/mol) | Literature molar ratio |
|---|---|---|
| E20 | ||
| DOPE | ||
| Cholesterol | ||
| DMG-PEG2000 |
Calculated component requirements
| Component | Normalized mol% | Amount (µmol) | Required weight (mg) |
|---|---|---|---|
| Total | 100.000% | — | — |
Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
Literature-reported performance for the cited formulation
Literature-reported4.99R18 fluorescence assay · pKa for becoming neutralMain article Figure 2b; SI Section 5.4
Literature-reported90-100 nmPost-formulation DLS characterization · Range reported for the five top SNPs E3, E7, E12, E15 and E20; not an E20-only exact valueSI Figure S76 and text, p. 135
Literature-reported<0.2Post-formulation DLS characterization · Reported for the SNP formulation panel; not an E20-only exact valueSI Figure S77 and text, p. 135
Literature-reported600 mU/mL24 h after 0.1 mg/kg IV hEPO mRNA · Reported as equivalent to MC3-DLin LNPs and 100-fold above the cited therapeutic thresholdMain article Figure 3b and text
Literature-reportedNo increase in IL-6, IL-1β or MIP-24 h after 1 mg/kg IV luciferase mRNA in LPS-pretreated mice · Traditional LNP comparators increased the measured cytokines in the LPS-pretreated modelMain article Figure 3c-f; SI Figures S95-S97
Literature-reportedAll E20-SNP-treated mice survived the 7-day observation periodAfter 1 mg/kg IV luciferase nanoplasmid DNA · All MC3-DLin LNP-pDNA-treated mice died within 24 hMain article Figure 3g-i and text; SI Section 6.2
Additional reported findings
E20-SNPs efficiently delivered luciferase mRNA to human PBMCs and did not induce any of the 14 cytokines evaluated in the reported experiment.
Human PBMCs from four donors; 2,000 ng/mL mRNA; 24 h · Main article Figure 4; SI Figures S90-S93E20-SNPs carrying IL-22 mRNA were reported to be more effective than the traditional LNP comparators in the LPS-induced acute-lung-injury model without exacerbating pre-existing inflammation.
BALB/c mice; 3 mg/kg intratracheal LPS followed 3 h later by 2.5 mg/kg intratracheal LNP/IL-22 mRNA · Main article acute-lung-injury section; SI Section 6.4The study reports that E20 SNPs are neutral or negatively charged at physiological pH and become positively charged under acidic formulation/endosomal conditions.
R18 apparent-pKa and pH-dependent zeta-potential experiments · Main article Figure 2b; SI Figures S78-S80Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetLiang D, Qi Y, Han H, et al. Charge-switching ionizable lipids lower the toxicity of lipid nanoparticles. Nature Nanotechnology. Published online September 8, 2026. DOI: 10.1038/s41565-026-02262-6
Structure: main Figure 2a and SI Figures S6, S14 and S51; formulation and N/P ratio: SI Section 4.1 and Table S1; performance: main Figures 2-5 and the cited SI figures.
Structure: main Figure 2a and SI Figures S6, S14 and S51; formulation and N/P ratio: SI Section 4.1 and Table S1; performance: main Figures 2-5 and the cited SI figures.